Granaticin B is a chemical compound classified as an anthracycline antibiotic, primarily known for its role in the field of medicinal chemistry and pharmacology. It is derived from the fermentation of certain species of Streptomyces bacteria. Granaticin B exhibits notable antitumor activity, making it of interest in cancer research and drug development. The compound is characterized by its complex polycyclic structure, which includes multiple fused aromatic rings, contributing to its biological activity. It typically displays a range of biological properties, including the ability to intercalate DNA, which disrupts cellular processes and can lead to apoptosis in cancer cells. Granaticin B's mechanism of action involves the inhibition of topoisomerase II, an enzyme critical for DNA replication and repair. Additionally, it may exhibit cytotoxic effects on various cancer cell lines, although its clinical use may be limited by potential side effects and resistance mechanisms. Overall, Granaticin B represents a significant compound in the study of anticancer agents and the development of novel therapeutic strategies.

Granaticin B

19879-03-9: Granaticin B is a chemical compound classified as an anthracycline antibiotic, primarily known for its role in the field of medicinal chemistry and pharmacology. It is derived from the fermentation of certain species of Streptomyces bacteria. Granaticin B exhibits notable antitumor activity, making it of interest in cancer research and drug development. The compound is characterized by its complex polycyclic structure, which includes multiple fused aromatic rings, contributing to its biological activity. It typically displays a range of biological properties, including the ability to intercalate DNA, which disrupts cellular processes and can lead to apoptosis in cancer cells. Granaticin B's mechanism of action involves the inhibition of topoisomerase II, an enzyme critical for DNA replication and repair. Additionally, it may exhibit cytotoxic effects on various cancer cell lines, although its clinical use may be limited by potential side effects and resistance mechanisms. Overall, Granaticin B represents a significant compound in the study of anticancer agents and the development of novel therapeutic strategies.

<p>Granaticin B inhibits the initial phase of RNA biosynthesis and exhibits activity against Gram-positive bacteria, mycobacteria (weak), and Trichomonas vaginalis, along with the ability to suppress tumor cells.</p>

CAS 19879-03-9

Granaticin B

Granaticin B

Ref: TM-TN10357